Cover image for GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2025 Prime Therapeutics’ GLP-1...

Cover image for GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2025 Prime Therapeutics’...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications. Prime Therapeutics /glp-1-pipeline-update-november-2024 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

publications GLP-1 Pipeline Update: November 2024 Quarterly view of the GLP-1 pipeline and anticipated indications November 21, 2024 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Vice...

publications GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications February 26, 2025 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief...

Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

publications GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications May 27, 2025 Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice...

Someone holds a GLP-1 pen needle in their hands.

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

publications Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development April 25, 2025 Editor-in-chief's message Welcome to the Prime...

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page...

New resource page offers the latest GLP-1 insights, research and perspectives

New report details the latest on GLP-1s

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

Real-world study of GLP-1 patients continues to deliver leading insights

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended